NCT03584958 is a clinical trial in Glaucoma, sponsored by Wills Eye.

Who is sponsoring NCT03584958?

NCT03584958 is sponsored by Wills Eye.

What condition does NCT03584958 study?

NCT03584958 studies Glaucoma, Ocular Hypertension.

Is NCT03584958 still recruiting?

NCT03584958 is currently status unknown. Last updated 29 March 2022.

Last reviewed 2022-03-29 · How we verify

NCT03584958

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparing Refractive and Visual Outcomes of MIGS and Traditional Surgeries

Status unknown Last updated 29 March 2022

What this trial tests

trial in Glaucoma in 150 participants. Status unknown.

Timeline

1 August 2018

Primary endpoint
31 December 2022

30 June 2023

Quick facts

Lead sponsor	Wills Eye
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	150
Start date	1 August 2018
Primary completion	31 December 2022
Estimated completion	30 June 2023
Sites	1 location across United States

Conditions studied

Glaucoma — all drugs for Glaucoma →
Ocular Hypertension — all drugs for Ocular Hypertension →

Sponsor

Wills Eye — full company profile →

Who can join

18 and older, any sex, with Glaucoma or Ocular Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary goal of this study is to evaluate refractive and visual outcomes in glaucoma patients who will be having either traditional glaucoma surgery or minimally invasive glaucoma surgery, also known as MIGS.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Glaucoma

Currently open trials in the same condition.

NCT07455786 — Modified Trabeculectomy After Failure of Combined Phaco With GATT · NA · recruiting
NCT07298356 — Automated Applanation Tonometry - Updated · NA · recruiting
NCT07217678 — Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use · Phase 4 · recruiting
NCT07145073 — Repetitive Transcranial Alternating Current Stimulation (rtACS) for the Treatment of Optic Neuropathies · NA · recruiting
NCT07209410 — Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanopro · Phase 4 · recruiting

Other Wills Eye trials

Trials by the same sponsor.

NCT05660447 — A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR · Phase 2, PHASE3 · active not recruiting
NCT05325996 — Evaluating Home Testing Devices for the Management of Glaucoma · NA · completed
NCT06130384 — Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection. · Phase 4 · completed
NCT04784234 — Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin · NA · terminated
NCT04459949 — Comparative Study of Sharkskin Versus Grieshaber Forceps During ILM Peeling · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03584958 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wills Eye
Last refreshed: 29 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03584958.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing